803 results on '"Castellano, D."'
Search Results
152. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02
153. A MULTICENTER VALIDATION STUDY OF GENETIC POLYMORPHISMS ASSOCIATED WITH TOXICITY AND EFFICACY OF SUNITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
154. Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
155. CheckMate 025 : a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
156. Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
157. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy
158. Application of the QFD methodology to plant layout evaluation
159. 1119 - FIERCE-21: Phase 2 study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUCC)
160. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
161. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
162. Cabazitaxel for metastatic castration-resistant prostate cancer: safety data from the Spanish expanded access program
163. 823P - Efficacy of therapies after progression to up-front docetaxel (D) with androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC)
164. 822P - Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
165. 899P - A phase II study investigating the safety and efficacy of neoadjuvent atezolizumab in muscle invasive bladder cancer (ABACUS)
166. 865PD - RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
167. Translational research in neuroendocrine tumors: pitfalls and opportunities
168. 1143 A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010)
169. Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma
170. 86 - Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052
171. 94 - Healthcare resource utilization in RANGE: Ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced or metastatic urothelial cancer
172. Overall material usage effectiveness (OME): a structured indicator to measure the effective material usage within manufacturing processes.
173. Dissolved Aluminium Concentrations Around The Submarine Volcanic Cone at El Hierro Island
174. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
175. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
176. Recomendations on the Management of Controversies in Advanced Castrate-Resistant Prostate Cancer
177. Correlation of PFS With Early Response of Chromogranin A and 5-hydroxyindoleacetic Acid Levels in Pts With Advanced Neuroendocrine Tumours: Phase III RADIANT-2 Study Results
178. 2637 Baseline circulating tumor cells (CTC) and serum heat shock protein 27 (Hsp27) levels are increased in advanced bladder cancer (BC) patients with poor prognostic factors: Results from the randomized phase 2 Borealis-1™ trial of first-line gemcitabine/cisplatin plus apatorsen or placebo
179. 2550 Phase Ib study of abiraterone acetate (AA) plus buparlisib (BKM120) or BEZ235 in patients (pts) with castration-resistant prostate cancer (CRPC)
180. 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
181. 2538 Response to cabazitaxel in patients with metastatic castrationresistant prostate cancer (mCRPC) poorly responding to docetaxel
182. 2541 Updated results of the FLAC European database of metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with life extending therapies in post-docetaxel (D) setting
183. 2543 Weekly cabazitaxel in “unfit” metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial
184. 2540 Experience with radium-223 as a systemic treatment for patients (pts) with castration-resistant prostate cancer (CRPC) out of a clinical trial in Spain
185. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma
186. 557 Early access protocol with abiraterone acetate for European patients with metastatic castration-resistant prostate cancer progressing after chemotherapy
187. Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations
188. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
189. Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
190. LBA4_PR - RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
191. 920TiP - Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ErbB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial
192. 862P - Treatment and outcome after Immune checkpoint inhibitors (ICI) in metastatic Urothelial Carcinoma (mUC): A European perspective
193. 857P - Pembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status
194. 87PD - Prospective study assessing the expression of angiogenesis-related genes as markers of anti-VEGFR2 response in advanced renal cell carcinoma
195. 212 - IMvigor010, a phase III study of adjuvant atezolizumab vs observation in patients (pts) with muscle-invasive urothelial carcinoma (UC)
196. 170 - Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052
197. 2196 - Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study
198. Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy
199. P091 - Circulating tumor cells as a predictive marker for response in patients with metastatic castrate resistant prostate cancer treated with Radium 223
200. LBA32_PR - Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.